<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30387871</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0142</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>02</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer</Title>                <ISOAbbreviation>Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.31798</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling consequence of neurotoxic therapies, yet factors that modulate the development and clinical impact of CIPN are poorly understood. This epidemiological analysis identifies risk factors for the incidence of CIPN.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data examined predictors of incident CIPN claims among 11,149 women aged 66 years or older with American Joint Commission on Cancer (AJCC) stage II to IV breast cancer (and no secondary cancer diagnosis or preexisting neuropathy) who received chemotherapy.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, new CIPN claims occurred for 8.3% of patients within 1 year of starting chemotherapy. Risk emerged approximately 3 months after the start of chemotherapy and increased throughout 1 year. Paclitaxel as part of first-line therapy increased CIPN risk 2.7-fold in comparison with nonneurotoxic agents (15.9% vs 5.0%), with lower incidence rates for carboplatin and paclitaxel (11.9%), carboplatin and docetaxel (9.3%), carboplatin alone (7.7%), and docetaxel alone (6.6%). The CIPN incidence rate was higher for women who at the time of their breast cancer diagnosis were relatively young (within this Medicare sample), were at AJCC stage II or III, were married or had an equivalent status, and had fewer comorbidities, but it did not differ by race/ethnicity or poverty level.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These Medicare claims database findings indicate that women aged 66 years or older with breast cancer are susceptible to CIPN from taxane and/or platinum compounds, with risk emerging approximately 3 months into treatment. Prospective studies of symptom emergence and clinical response (eg, stopping chemotherapy and adjunctive treatments) are indicated to determine how best to inform patients of this risk and to manage CIPN in this population.</AbstractText>                <CopyrightInformation>Â© 2018 American Cancer Society.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Greenwald</LastName>                    <ForeName>Mark K</ForeName>                    <Initials>MK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ruterbusch</LastName>                    <ForeName>Julie J</ForeName>                    <Initials>JJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beebe-Dimmer</LastName>                    <ForeName>Jennifer L</ForeName>                    <Initials>JL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Simon</LastName>                    <ForeName>Michael S</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Albrecht</LastName>                    <ForeName>Terrance L</ForeName>                    <Initials>TL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schwartz</LastName>                    <ForeName>Ann G</ForeName>                    <Initials>AG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karmanos Cancer Institute, Detroit, Michigan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P30 CA022453</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>HHS N261201300011I</GrantID>                    <Agency>U.S. Department of Health and Human Services</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>P30 CA022453</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer</MedlineTA>            <NlmUniqueID>0374236</NlmUniqueID>            <ISSNLinking>0008-543X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Medicare claims</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">chemotherapy-induced peripheral neuropathy</Keyword>            <Keyword MajorTopicYN="N">epidemiology</Keyword>            <Keyword MajorTopicYN="N">risk factors</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30387871</ArticleId>            <ArticleId IdType="doi">10.1002/cncr.31798</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>